Methodological study demonstrates improved efficiency of median-based group acceptance sampling in skewed product lifetime testing, indicating reduced sample size and inspection costs.
In this study, we present a median-based group acceptance sampling plan (GASP) under a truncated life test, assuming that the lifetime of an item follows a flexible three-parameter Poisson-Lomax distribution (PLD). The median lifetime is used as a robust quality index to determine the design parameters of the sampling plan, including the acceptance number, number of groups, and test termination time, while satisfying the specified producer and consumer risks. The performance of the proposed plan is evaluated using operational characteristic (OC) curves and extensive numerical results. The findings indicate that the proposed GASP efficiently reduces the required sample size, inspection time, and cost, particularly for skewed and heavy-tailed datasets. Furthermore, the unknown parameters of the PLD distribution were estimated using the maximum likelihood estimation (MLE) method based on multiple real-life datasets to demonstrate the model applicability. A comparative analysis with existing GASP based on competing lifetime distributions demonstrates that the proposed GASP achieves superior efficiency, requiring fewer testing units while maintaining the specified risk levels.
No takes yet. Share an insight, caveat, or question.
Kanwal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: